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Case presentation
A 28-year-old man first became aware of elevated blood
pressures during his early teens because he was often told
that his blood pressure was "high" during routine pre-
employment physical examinations. Five years ago, he
noted episodic confusion, dizziness, blurring of vision,
slurring of speech, epistaxis, and occipital headaches, but
did not consult a physician. One year later, he was seen in
an infirmary while in the army and his blood pressure was
180/130 mm Hg; methyldopa in a dosage of 1 g daily was
prescribed. Shortly thereafter, he suffered a hypertensive
crisis with encephalopathy. His blood pressure at that
time was 240/160 mm Hg. Evaluation for hypertension
was carried out at an army medical center. An iv. uro-
grain revealed only an enlarged (17.5 cm) left kidney with
otherwise normal architecture and function. A renal scan,
sonogram, and cytoscopic examination failed to reveal
evidence of a right kidney, and it was thought to be con-
genitally absent. Results of urinalysis were normal, 24-
hour urine protein excretion was 9 mg, and the endoge-
nous creatinine clearance was 87 mllmin. Chest radio-
graph and electrocardiogram (EKG) were normal. The
serum creatinine concentration was I mg/l00 ml. On
several determinations, normal laboratory values were
found for serum electrolytes, calcium, and uric acid, thy-
roid function, blood sugar, and 24-hour excretion of
vanillylmandelic acid (VMA), metanephrines, and cate-
cholamines; the Regitine test was negative on two
occasions.
Over the next 2 years, the patient had three additional
hypertensive crises with a residual mild right hemipare-
sis, dysarthria, and a right superior temporal visual field
defect. Treatment with a variety of medications including
diuretics, methyldopa, guanethidine, propranolol, cloni-
dine, and hydralazine yielded relatively poor control of
the patient's hypertension.
Two years ago, he was admitted to the New England
Medical Center Hospital (NEMCH) with exertional angi-
na, paroxysmal nocturnal dyspnea, orthopnea, episodic
dizziness, and dysarthria. The patient's history revealed
that he had smoked about 10 cigarettes per day for 6
years, and that both parents and his only sibling were hy-
pertensive. Physical examination revealed the following
data: blood pressure, 170/115 mm Hg; optic fundi, mild
arteriolar narrowing; cardiac examination revealed nor-
mal Si and S2, an S4 at the apex, and a Grade IIJVI sys-
tolic ejection murmur that radiated to the carotid arteries
and was best heard at the lower left sternal border; ab-
dominal examination revealed no epigastric or flank
bruits; peripheral pulses were intact and synchronous
with no bruits; neurologic examination revealed evidence
for a cerebral infarction in the region of the left middle
cerebral artery and anterior cerebral artery. The remain-
der of the examination was normal. Laboratory findings
revealed the following data: serum creatinine, 1.2 mg;
blood urea nitrogen (BUN), 15 mg/l00 ml; hemogram,
serum electrolytes, plasma lipids, AM and PM cortisols,
T4 and T3 uptake, serum calcium, serum phosphorus, to-
tal serum protein, serum albumin, serum bilirubin, blood
glucose, serum uric acid, transaminases, and several de-
terminations of urinary VMA, metanephrines, and cate-
cholamines were within normal limits; urine cultures
showed no growth; urine sediment was unremarkable;
peripheral plasma renin activity (PRA) on an 80 mEq so-
dium diet and following 4 hours in the upright position
was 12.2 ng/mllhr; chest radiogram was within normal
limits; EKG showed incomplete right bundle-branch
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block but no other abnormalities; i.v. urogram revealed
the left kidney to be 18 cm in length with a normal neph-
rogram and collecting system, but there was no evidence
of a right kidney; computerized tomographic (CT) scan of
the abdomen showed no evidence of a right kidney; elec-
troencephalogram, brain scan, CT scan of the head, and
lumbar puncture were within normal limits. The recent
neurologic symptoms were thought to represent transient
ischemic attacks; anticoagulants were not given. Satisfac-
tory blood pressure control was achieved on a daily regi-
men of clonidine (0.8 mg), propranolol (120 mg), hydro-
chiorothiazide (100 mg), and spironolactone (100 mg).
After discharge, the patient continued to experience
exertional chest pain relieved by rest and nitroglycerin,
episodic dizziness, dysarthria, and paroxysmal nocturnal
dyspnea. One and one-half years ago, he had another hy-
pertensive crisis associated with loss of consciousness,
which was treated successfully with diazoxide at another
hospital. He was readmitted to NEMCH 1 year ago with
uncontrolled hypertension (180/120 mm Hg) while on a
regimen of clonidine, propranolol, guanethidine, hydro-
chlorothiazide, and spironolactone. The physical exami-
nation was unchanged from the earlier admission. The
serum creatinine concentration was 1.1 mg, and the BUN
concentration was 12 mg/100 ml. An EKG showed an in-
complete right bundle-branch block, a chest radiograph
was normal, and an echocardiogram showed mild left
ventricular hypertrophy. Minoxidil was added to the ther-
apeutic regimen, and guanethidine was discontinued. At
discharge, the blood pressure was 124/94 mm Hg.
The patient continued to experience episodes of severe
occipital headache associated with neck stiffness, diapho-
resis, dizziness, blurring of vision on the right side, and
slurred speech; blood pressures taken at home during
these episodes were 170-190 systolic to 120-124 diastolic
mm Hg. The daily therapeutic regimen included minoxidil
(40 mg), clonidine (0.8 nig), propranolol (400 mg), and fu-
rosemide (80 rug).
Eight months ago, the patient was readmitted to
NEMCH. While following the above drug regimen, blood
pressures were 150-190 systolic to 100-120 diastolic mm
Hg. Physical examination was unchanged. The serum
creatinine concentration was 1 rug, and the BUN was 13
mgIlOO ml. Chest radiograph and EKG were unchanged.
A renal arteriogram revealed a single left kidney with no
abnormalities of the major left renal artery, an accessory
artery to the lower pole, or their branches; there was
some minimal irregularity of the distal intrarenal
branches; there was no evidence of a right renal artery or
kidney. Venous sampling for measurement of PRA was
obtained from several sites with the following results:
lower inferior vena cava, 8.3; left main renal vein, 19.6;
left upper venous branch, 13.2; midleft venous branch,
10.3; and lower left venous branch, 24.9 ng/ml/hr.
Discussion
DR. E. HABER: This patient presents a most un-
usual and interesting problem. The pertinent facts
are that the patient is a young man of 28 years who
is known to have had an elevated blood pressure
since his early teens, that is, for more than 10 years;
he had symptoms for at least 5 years that included
hypertensive encephalopathy on several occasions,
resulting in residual neurological deficits, hemipare-
sis, dysarthria, and a visual field defect, as well as
angina pectoris. Indeed, this patient's course repre-
sents a telescoped history of the ravages of hyper-
tension. The normal findings on cerebral CT scan
may well indicate lacunar disease, and if the pa-
tient's symptoms truly represent angina pectoris he
also has significant coronary artery stenosis. The
family history is of special interest in that both par-
ents and a sibling also suffer from hypertension.
The patient's blood pressure has been remarkably
resistant to treatment. Sympatholytics, vasodila-
tors, and diuretics were administered with little last-
ing benefit. Typically, adequate blood pressure con-
trol was attained in the hospital setting, but shortly
thereafter the patient reappeared with markedly ele-
vated systolic and diastolic pressures.
I would like to concentrate first on a detailed dis-
cussion of the patient's problem, particularly with
respect to narrowing the possible causes of his hy-
pertension, and then turn to a more general dis-
cussion of the issue suggested by this case. Physi-
cians are most often interested in mechanisms, par-
ticularly mechanisms that can be explained on the
basis of pathophysiology. It is for this reason that
an almost undue amount of attention is focused on
secondary causes of hypertension, when they may
be implicated at most in 5% ofpatients who present
with elevated blood pressure. The first sensible
question to address is whether or not this patient
has reached the accelerated or malignant stage of
essential hypertension. In favor of this diagnosis is
the very strong family history of hypertension.
Perhaps the most apt description for accelerated
hypertension is a state in which end organ damage
is compressed into a brief time period. This mani-
festation occurs in approximately 1% of hyperten-
sive patients, usually in those whose disease is
poorly controlled or untreated. The renin system is
believed to play a major role in the development of
malignant hypertension though patients with malig-
nant hypertension and normal PRA have been re-
ported rarely. In this patient, the sole chemical ab-
normality uncovered in the course of a very exten-
sive laboratory evaluation was an increase in PRA.
Patients with malignant hypertension characteristi-
cally have severe hypertension, focal neurological
deficit, left ventricular failure, and myocardial is-
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chemia, all of which this patient manifests. Most pa-
tients with malignant hypertension also have renal
failure, notably absent here.
Although it is difficult to exclude accelerated hy-
pertension as the primary diagnosis, certain ana-
tomical features uncovered on contrast radiography
suggest that secondary hypertension should be con-
sidered carefully. The causes of secondary hyper-
tension that could reasonably be listed in a dif-
ferential diagnosis in this patient include coarctation
of the aorta, pheochromocytoma, primary paren-
chymal renal disease, primary aldosteronism, and
hyperreninemia secondary to an intrarenal lesion.
This patient's comprehensive examination allows
me to exclude most of these possibilities. A creati-
nine clearance of 87 mllmin in the presence of a
single kidney with normal values for BUN and
serum creatinine, minimal urinary protein content,
and an unremarkable urine sediment makes paren-
chymal disease a most unlikely cause of chronic hy-
pertension. The elevated renin activities immediate-
ly serve to exclude primary aldosteronism, which is
always associated with depressed renin activity.
Normal urinary excretions of catecholamines,
VMA and metanephrine eliminate the possibility of
pheochromocytoma presenting as nonparoxysmal
hypertension. The observation during the physical
examination that pulse delays were not observed
and the presence of normal chest radiograms with-
out characteristic rib notching or other pathogno-
monic signs exclude coarctation of the aorta.
I must then focus on the renal anatomical abnor-
mality and the elevated PRA. First, I must be con-
vinced that there is not a very small shrunken kid-
ney on the right side, which is not manifesting its
presence in any way except by excess renin secre-
tion. The data gathered indicate that a right kidney
was not detected by i.v. urography, by angiogra-
phy, by renal scan, by cystocopy—presumably no
ureter was seen—by sonography, and ultimately by
body CT scan. All of these methods could miss a
very small kidney of minimal excretory function. It
might be seen only by selective renal venography
[11. There is one finding, however, that tends to ex-
clude such a kidney as the primary source of hyper-
reninemia. It is characteristic that when the major
contribution of elevated PRA is from one kidney,
the contralateral normal kidney is marked by sup-
pression of renin secretion. Yet, what was found
was an abnormally elevated renin excretion from
the left main renal vein (19.6 ng/mllhr). If there had
been a cryptic right kidney producing renin, I would
have expected the concentration of renin in the left
main renal vein to be close to that of the lower infe-
rior vena cava. Whether there is a right kidney pro-
ducing renin in addition to the overproduction of re-
nm in the left kidney unfortunately cannot be ascer-
tained because we do not have a vena cava sample
above the renal veins. If there were still further aug-
mentation of renin concentration at that sampling
point, a renin secreting right kidney could be postu-
lated.
The focus of interest and the most likely patho-
genetic factor in the hyperreninemia is the sole large
left kidney. The lower left venous branch of this
kidney contributes twice as much renin activity
(24.9 ng/mllhr) as the upper branch (13.2 ng/mllhr)
and the midbranch (10.3 ng/mllhr). If one were com-
paring the arteries of two contralateral kidneys
rather than branches of a single kidney's arteries,
these differences would satisfy most criteria for the
diagnosis of unilateral renovascular hypertension.
Thus, the most interesting question is whether or
not the lower pole of the single kidney could be re-
sponsible for renin-dependent hypertension in this
patient, and, if so, what are the possible etiologies.
Although I have not found a report of a unilateral
single kidney, only a part of which was contributing
to renin-dependent hypertension, such reports are
common when two kidneys are present [2]. Perhaps
the best precedent for a hyperreninemic lesion in a
single kidney is the report by Golden et al [3] of a
patient with hypertension who was shown to have
stenosis of the right renal artery of a single horse-
shoe kidney. Renin activity in the right renal vein
was more than twice that of the left renal vein.
Schambelan et al 112] identified 14 patients in
whom selective renal vein sampling uncovered seg-
mental lesions contributing to a hyperreninemic
syndrome. Diagnoses included segmental infarc-
tion, renal artery branch stenosis, and renin-se-
creting tumor. Other potential causes of segmental
renal lesions that could be responsible for hyper-
reninemia include renal artery dissection, intrarenal
vascular abnormalities, renal cyst, and congenital
segmental renal hypoplasia. The availability of a
good renal angiogram allows me to relegate some of
these diagnoses to a low order of probability.
Spontaneous renal artery dissections occurring in
hypertensive patients [4] are a cause of renal artery
stenosis but, again, should be reasonably apparent
in the relatively large branches of the main renal ar-
tery. Babka, Cohen, and Sode [5] reported a soli-
tary renal cyst associated with renin-producing hy-
pertension. The cyst was large, however, and read-
ily identified on contrast studies. Segmental renal
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infarcts must also be considered but are usually
readily seen on angiography. Segmental renal hypo-
plasia, the Ask-Upmark syndrome, has been docu-
mented as a cause of renin-dependent hypertension.
Royer et a! [6] reviewed 36 cases of this syndrome
in which the patients first presented between 8 and
20 years of age. Although females predominated, 11
of the 36 patients were male; all were hypertensive.
In 1 of these patients, only the upper segment of a
single kidney was affected and its surgical removal
resulted in cure of hypertension. The Ask-Upmark
kidney does, however, present a rather clear-cut ra-
diologic picture [7]. The excretory urogram may
show a nodular configuration of the kidneys with a
distorted pelvocalylceal pattern indicating varying
degrees of dilatation, elongation, and compression.
Displacement of calyces is probably due to com-
pensatory hypertrophy of intervening renal tissue.
Arteriogram shows displacement of interlobar and
arcuate branches by the same masses of regenera-
ting renal tissue. None of these findings was appar-
ent on review of the angiogram in this patient, so
this diagnosis can readily be excluded.
It is not possible, however, to exclude the diagno-
sis of a renin-secreting tumor. One of the first pa-
tients described by Robertson et al [8] was a 16-
year-old boy who presented with severe hyper-
tension that was unresponsive to treatment. Both
an i. v. urogram and a renal angiogram were entirely
normal. A tumor was not discovered until a second
laparotomy was performed; at which time, its re-
moval resulted in a cure of hypertension. A very
well-studied case reported by Conn et al [9] was al-
so characterized by a very subtle presentation of
the tumor on the angiogram. It was missed at the
time of the first angiogram when the patient was al-
ready markedly hypertensive; it was seen on a sec-
ond angiogram 2 years later. At nephrectomy, the
tumor was very difficult to visualize from the kidney
surface. Five patients reviewed by Conn et al [91
manifested hypertension for periods of 9 months to
6 years prior to operative cure. The patients were
between 16 and 37 years old at the time the defini-
tive diagnosis was made. Most renin-secreting tu-
mors are benign lesions arising from juxtaglomeru-
lar cells, though an occasional Wilms' tumor may
secrete significant quantities of renin [10]. Thus, a
small renin-producing tumor in the lower pole can-
not be excluded on the basis of the data available.
A branch renal artery stenosis should be seen
rather readily although an asymmetric lesion might
be missed in a single view. At this patient's age the
etiology would most likely be fibromuscular hyper-
plasia, which does tend to be more symmetrical
within a vessel as opposed to the classical asymme-
try of atherosclerotic plaques.
How should one proceed in the treatment of this
28-year-old man who has already suffered the rav-
ages of hypertension in a compressed and acceler-
ated course? Medical management has been remark-
ably unsuccessful considering all of the anti-
hypertensive drugs available for routine clinical
use. Are the drugs or drug combinations used inef-
fective, or is lack of patient compliance outside the
hospital the cause of poor control? The treatment of
hypertension requires close patient cooperation,
and unwillingness to follow a prescribed program
has been documented as a frequent cause of thera-
peutic failure [111. Regardless of the reasons for in-
effective medical management, however, what ad-
ditional diagnostic tests might be performed to re-
veal a surgically remediable lesion? Would a
surgical attack be justified in a patient with a single
kidney? Is there an alternative to partial nephrecto-
my or bypass surgery?
Source of renin and control of its secretion
I should now like to turn to discussion of the re-
nm system and its role in normal and pathologic
blood pressure control in order to put this patient's
problems in perspective. Renin is synthesized and
stored in membrane bound cytoplasmic granules by
cells at the vascular pole of the renal glomerulus
[12, 13]. Both the afferent and efferent arterioles are
anatomically and functionally associated with a
group of specialized cells at the origin of the distal
tubule that forms the macula densa. The entire
structure is referred to as the juxtaglomerular ap-
paratus." This site is the center of a feedback loop,
which serves to regulate blood pressure and prob-
ably intravascular volume by modulating the rate of
renin secretion. Factors directly affecting the rate of
secretion of renin by the juxtaglomerular apparatus
include sodium concentration in the distal tubule,
blood pressure in the afferent arteriole, plasma an-
giotensin II concentration, and the impulse traffic of
the renal sympathetic nerves.
The secretion of renin ultimately results in the
production of angiotensin II, which has both direct
and indirect effects on blood pressure and blood
volume. Angiotensin II is a potent vasoconstrictor,
thereby directly raising blood pressure. It also acts
on the central nervous system to increase peripher-
al vascular resistance. The adrenal gland may be
stimulated by angiotensin II or its metabolic prod-
uct, angiotensin III, to produce aldosterone, a po-
tent mineralocorticoid that promotes sodium reten-
tion in the renal tubule. Sodium retention, in turn,
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increases vascular volume and blood pressure.
The feedback loop is completed when vasocon-
striction and sodium retention increase blood pres-
sure and decrease renin secretion by acting directly
on the baroreceptors in the juxtaglomerular appa-
ratus. Stimulation of a chemoreceptor for sodium in
the kidney and several vascular baroreceptors lo-
cated elsewhere in the circulation also serve to reg-
ulate renin secretion. These concepts are reviewed
in considerably more detail elsewhere [141.
Chemistry of the renin—substrate reaction
Renin has no known direct physiologic effect but
acts only to cleave its substrate, angiotensinogen,
which is an alpha II globulin synthesized in the
liver. The amino acid sequence of the amino termi-
nal 14 residues of renal substrate is known (Fig. 1).
Renin cleaves between two leucine residues at posi-
tion 10 and 11 to release the decapeptide angioten-
sin I. Angiotensin I is in turn cleaved between resi-
dues 8 and 9 by a converting enzyme to yield the
active pressor hormone, angiotensin II. Amino-
peptidases further degrade angiotensin II by remov-
ing the amino terminal aspartic acid. The resultant
heptapeptide, sometimes called angiotensin III, is
believed by some investigators to be the primary
mediator of adrenal cortical aldosterone secretion
[15, 161. Angiotensin II and III have very short half-
lives in the circulation and are further degraded to
smaller inactive peptides [171.
The past several years have seen the develop-
ment of interest concerning possible renin pre-
cursors or zymogens. A number of observations
have been made that on the surface appear con-
tradictory. In evaluating various reports two critical
questions which must be kept in mind are (1) What
is the precise definition of renin? and (2) Is the en-
zyme that is examined in vitro the same material
that is produced in vivo by the kidney?
A precise definition of renin in molecular terms is
not yet possible, since the enzyme has only recently
been fully purified, and structural information is not
yet available. To define it in functional terms can be
quite misleading. Many investigators depend on an
in vivo pressor response. Clearly, the number of po-
tential substances giving such a response is great;
even if it can be demonstrated that this response is
mediated by angiotensin II, renin need not be in-
volved. If the in vitro production of angiotensin I
from renin's protein substrate, angiotensinogen, is
accepted as the sole criterion, one may be misled;
other enzymes may degrade this substrate in the
same way. For example, pepsin cleaves renin sub-
strate to produce angiotensin I [181. Neutralization
Des-Asp-ne5 angiotensin Angiotensinase
'Angiotensin III"?2345678
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Fig. 1. Biochemistry of the renin-angiotensin system. 11e5-angio-
tensin contains isoleucine in the 5 position and is the form of
peptide that occurs in man. The existence of des-Asp'-angioten-
sin II as an intermediate in the pathway has not been definitely
established. (Data taken from Ref. 14. Reprinted by permission
from the New England Journal of Medicine.)
of enzyme activity by antibodies is used as another
criterion of identification, but may also be mis-
leading because most of the antigens utilized in elic-
iting antibody have been relatively impure mix-
tures. It is conceivable that antibodies to several
different enzymes may be present in the antisera
used. Although antibodies specific for highly puri-
fied mouse submaxillary gland renin that cross react
with mouse plasma renin are available {19], it is not
at all certain that they possess unique specificity for
this enzyme. Related acid proteases may share
common antigenic determinants. The close relation-
ship of the catalytic sites of this set of enzymes has
already been defined by the demonstration that pep-
statin inhibits the action of a number of seemingly
unrelated proteases, such as pepsin, rennin, cathep-
sins A and D, and renin [20, 211.
Are there prorenins?
Larger molecular size renins in the kidney. Some
of the earliest accounts of purification attempts of
renin suggested multiple components. Skeggs et al
[22] in 1967 demonstrated that hog renin prepared at
pH 7.0 was converted by exposure at pH 2.4, or by
longer exposure at pH 5.0, to an enzyme of higher
specific activity but similar Michaelis constant.
Subsequently, the same group showed that human
kidney renin could be isolated in multiple molecular
forms, all of which had approximately the same mo-
Renin substrate
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lecular weight (approximately 39,500 daltons) [231.
Most recently, this group [24] reexamined hog kid-
ney and found that whether kidney was extracted at
a neutral or at an acid pH, a relatively constant frac-
tion of higher molecular weight material (57,000 to
59,000 daltons) was observed on gel filtration. This
material comprised about 20% of total renin activi-
ty; it could neither be activated nor changed in its
molecular size by exposure to acid.
In contrast, a number of other investigators dem-
onstrated the presence of a high molecular weight
form of renin, which could be shown to increase in
enzymatic activity by acid exposure. In some in-
stances, this increase in activity was accompanied
by a decrease in molecular weight. In other reports,
apparent molecular size did not change with activa-
tion. Rubin [251 observed an activation of renin ac-
tivity in crude extracts of hog kidney on acid-
ification. This activation could not be demonstrated
with more purified materials, suggesting the partici-
pation of a protease. Lumbers [26] demonstrated a
marked increase in renin activity in human amniotic
fluid after acidification. Skinner et al [27] confirmed
this observation and indicated that approximately
80% of the renin present in amniotic fluid was in-
active and could be activated by acidification. Mor-
ris and Lumbers [281 separated renin activity from
the activating factor. At pH 1.5 renin is denatured,
but an activating principle remains, which when
added to relatively inactive renin can increase its
specific activity. Trypsin and to a lesser extent chy-
motrypsin were also shown to activate renin. Later
Morris and Johnston [291 isolated renin-containing
particles from the rat kidney by isopyknic gradient
centrifugation and showed that these particles con-
tained a relatively inactive form of renin that could
be activated by acid treatment. As in all other re-
ports, the molecular size of active renin was close
to 40,000 daltons (37,000 daltons in this instance).
Morris and Johnston suggested that the inactive
form of renin was only of slightly greater molecular
weight (44,000 daltons).
Boyd [30] was careful to extract hog kidneys at a
neutral pH in order to avoid acid activation early in
the purification procedure and observed two forms
of renin, one having molecular weight of 60,000 dal-
tons and the other 40,000 daltons. The larger molec-
ular weight renin was characterized by an attenu-
ated and more prolonged pressor response in vivo
than the lower molecular weight form. Acidification
to pH 2.5 at 4° C increased the pressor response of
the higher molecular weight renin, but did not
change that of the lower molecular weight form.
This activation could be effected by high concentra-
tions of sodium chloride and several chaotropic
agents. Activation could also be effected simply by
diethylaminoethyl (DEAE)-cellulose chromatogra-
phy. All of these maneuvers decreased the molecu-
lar size of renin as it was activated. A fraction could
be isolated on DEAE-cellulose chromatography,
which combined with the lower molecular weight
active form of renin to increase its molecular size
and decrease its activity. Leckie and McConnell
[31] reported very similar observations on rabbit
kidney renin. As in Boyd's report, renin was quan-
tified by in vivo pressor response. The active form
of renin had a molecular weight of 37,000 daltons,
the inactive form 55,000 daltons. Acid treatment of
the inactive form reduced its molecular size to that
of the active form and increased pressor response in
vivo. An inhibitory fraction of 13,000 daltons was
isolated by DEAE-cellulose chromatography. Upon
addition of this fraction to active renin, a time-de-
pendent drop in renin activity could be demon-
strated with a concomitant increase in molecular
size. On the basis of these observations, a non-
covalent association between renin and inhibitory
protein was implied.
Slater and Haber [32] extracted human kidneys at
neutral pH in the presence of several protease in-
hibitors. They demonstrated a fraction possessing
renin activity that had a molecular weight of 63,000
daltons by gel filtration. This fraction could be fur-
ther purified by column chromatography and affini-
ty chromatography on a (D-Leu6) octapeptide col-
umn [33], which yielded a purified product having
the same molecular weight. Acidification of the
larger molecular weight form of renin early in the
purification process followed by gel filtration result-
ed in an increase in total renin activity. Following
further purification, however, acidification did not
alter renin activity, suggesting that activation was
effected by a protease that was removed during the
purification procedure. These investigators were
able to relate the two renin activities by demonstrat-
ing that antibodies raised to the larger molecular
weight form of renin inhibited activities of both
forms. Inagami and Murakami [34] demonstrated
three forms of renin from hog kidney having molec-
ular weights of 140,000, 61,000 and 42,000 daltons.
Great care was taken in the extraction procedures
to avoid action of endogenous proteases or ex-
posure to acidic pH. Higher molecular weight forms
were purified by affinity chromatography, gel filtra-
tion, and ion-exchange chromatography to homoge-
neity by both polyacrylamide gel electrophoresis
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and electrofocusing. The specific enzymatic activity
of the 61,000 dalton form of renin was 9% as active
as the 42,000 dalton form of renin on a molar basis.
The largest form of renin (mol wt, 140,000 daltons)
was only 0.03% as active on a molar basis as fully
active renin. These investigators have not yet re-
ported on the interconversion among the various
forms.
Larger molecular size renins in plasma. Sealey
and Laragh [35] observed an increase in PRA in the
plasma of normal subjects and of patients with es-
sential hypertension after prolonged storage of the
plasma at —20° C. More recently, these investiga-
tors [36] report that activation can occur on storage
of human plasma for 4 days at —5° C and pH 7.4,
and that activation may be mediated by proteases
[37]. Leckie and McConnell [38] show similar acti-
vation of human plasma by acidification. Day and
Leutscher [391 demonstrated a higher molecular
weight form in some human plasmas (approximate-
ly 63,000 daitons) that differed in size from normal
plasma renin (43,000 daltons). Exposure of the high-
er molecular weight renin at pH 3.0 to 3.6 or brief
incubation with pepsin resulted in a tenfold in-
crease in enzymatic activity. This larger form of re-
nm was also found in tumor extracts and in amniotic
fluid, but was not present in normal plasma or kid-
ney extracts. Patients with certain disease states,
such as hypertension associated with renal tumors
or diabetes with neuropathy, also showed evidence
of the larger molecular weight form of renin in their
plasma [40, 41]. In their hands, acid activation did
not significantly alter the molecular size of the high-
er molecular weight form of renin coincident with
activation [39]. Derkx et al [421 demonstrated that
an inactive form of renin was released by the kidney
in patients with renal artery stenosis. Isoproterenol,
tilting or diazoxide, in both normotensive and es-
sential hypertensive individuals increased the con-
centration of the active form of plasma renin and
reduced that of the inactive form. An inverse physi-
ological relationship between inactive and active re-
nm was suggested.
Mailing and Poulsen [19] measured high molecu-
lar weight forms of renin in plasma both by enzy-
matic activity and direct radioimmunoassay using
an antibody elicited by highly purified mouse sub-
maxillary gland renin. Three components were
found: the well-recognized active renin at an appar-
ent molecular weight of 40,000 daltons; a 70,000 dal-
ton form; and an 800,000 dalton form. The specific
activity of the higher molecular weight forms was
considerably less than that of the 40,000 dalton form
when the amount of renin measured by enzymatic
assay was compared to that quantified by the direct
radioimmunoassay. Most recently, Nielson, Mal-
ling and Poulsen [43] demonstrated that the 800,000
dalton form can be converted to the active 40,000
dalton form by storage, exposure to acid, and limit-
ed proteolysis. The 70,000 dalton form can be acti-
vated by acid and limited proteolysis. The 70,000
dalton form, however, does not change molecular
weight with activation.
How can these contradictory data be resolved?
Certainly some differences can be accounted for by
the action either of renal proteases on the com-
ponents being studied or artifactual ex vivo associa-
tion among proteins. Discrepancies in molecular
size, covalent integrity of larger forms of renin, and
either facility or failure to demonstrate inter-
conversion of larger to smaller molecular weight
forms may well be related to the care various inves-
tigators have taken either to exclude protease activ-
ity or to prevent nonspecific aggregation from oc-
curring in the course of preparation. In evaluating
these reports, it is prudent to question whether or
not the enzymatic or biological activity being stud-
ied is renin or that of another enzyme that releases
angiotensin. Alternatively, all the large molecular
weight forms examined in plasma may simply repre-
sent the association of renin with one or another
carrier protein. It is only through examination of
highly purified materials and detailed molecular or
immunologic characterization that the very impor-
tant question of whether or not renin has several
larger molecular weight biosynthetic precursors can
be answered.
Determinants of renin secretion in normal man.
In the normal unstressed individual, the major de-
terminants of renin secretion are posture, sodium
intake, and time of day. In a study of normal con-
trols [44], very low levels of both renin activity and
plasma aldosterone concentration were observed at
the highest sodium intake, 240 mEq/day. There
seemed to be little variation during the course of the
day. At 100 mEq sodium intake, renin activity was
low during sleep but rose by a factor of nearly 10,
reaching a maximum by the middle of the day. By 8
P.M., it declined to early morning levels, even
though the subjects remained upright at normal ac-
tivity throughout this period. Plasma aldosterone
levels followed renin activity faithfully. At a low so-
dium intake, 10 mEq/day, nighttime levels of both
renin and aldosterone were higher and plasma al-
dosterone seemed to peak at a still higher level. On
the other hand, plasma cortisol, which reflects
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adrenocorticotropic hormone (ACTH) secretion,
followed a different and independent diurnal pat-
tern. Cortisol peaked at 8 A.M. and gradually fell
during the course of the day. Its cycle was not at all
correlated with either renin or aldosterone, and the
magnitude of peak plasma concentration was inde-
pendent of sodium intake. If normal individuals
were kept in bed for 24 hours, diurnal cycles of re-
nm secretion could still be observed, but the height
of the peaks was considerably blunted [45, 461.
Inhibitors of the renin-angiotensin system
The ability to measure renin activity and an-
giotensin II concentration by radioimmunoassay
proved to be most helpful to the physiologist and
clinical investigator in understanding the response
of the renin-angiotensin system to a variety of inter-
ventions. It was not until specific inhibitors were
available, however, that it became possible to de-
fine precisely the role of renin in any given physio-
logic or pathologic situation. Inhibitors may (1) in-
terfere with the action of renin on its substrate, (2)
block converting enzyme in its action on angioten-
sin I to produce angiotensin II, and (3) compete in
the interaction of angiotensin II with its receptor
site in blood vessels or in the adrenal cortex (Fig.
2).
Renin inhibitors. Antirenin antibody was the
earliest inhibitor used in physiologic studies [47, 48,
49]. The removal or inactivation of renin from the
circulation with a specific antibody should also re-
move whatever physiologic consequences its pres-
ence might engender. Antirenin antisera lowered
blood pressure in experimental renovascular hyper-
tension, but the specificity of the antibody, and con-
sequently the interpretation of the results, was un-
certain. Since extracts of kidney of varying purity
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Fig. 2. Sites of action of inhibitors of the renin-angiotensin
system.
were used as the immunogen, the antibodies pro-
duced were likely to be highly heterogeneous. One
would expect to find antibodies directed against a
variety of renal cellular constituents, including
functionally important membrane structures and re-
ceptors. Such antibodies may simultaneously affect
several of the kidney's functions, thereby obscuring
or distorting the result of their inhibition of renin.
Even if functionally homogeneous renin antibodies
were available, the reaction of this antibody with its
antigen would lead to the formation of immune
complexes, which in turn could activate the com-
plement system. A number of peptides released in
the course of complement activation have inde-
pendent vascular effects, again confounding the in-
vestigator. If the antibody were raised in a heterolo-
gous species, it may only be used for a short time
because the formation of antibodies to a foreign
protein would result in rapid elimination as immune
complexes.
Pepstatin is a nonspecific acid protease inhibitor
that also inhibits renin activity [50]. Conflicting data
in earlier experiments cast doubt on its efficacy in
vivo [51]. Most recently, Menard et al have solubil-
ized pepstatin by the addition of a hydrophilic resi-
due to the C-terminal part of the molecule [52]. This
resulted in a 100-fold increase in water solubility.
Inhibitory constants for soluble and native pepsta-
tin did not differ significantly using either native
angiotensinogen or the synthetic tetradecapeptide
as a substrate with hog, rat, and human renin as the
enzyme. Solubilized pepstatin was effective in vivo
in decreasing blood pressure that had been raised in
binephrectomized rats with purified hog renin. A
fall in blood pressure was also noted when the in-
hibitor was injected into rats rendered hypertensive
by ligation of the aorta between the renal arteries.
Thus a novel approach is available in the use of
modified pepstatins in investigation of the renin-
angiotensin system.
A new class of competitive renin inhibitors based
on substrate structure has now been synthesized
[53, 54]. Skeggs et al reported that octapeptide I
(His-Pro-Phe-His-Leu-Leu-Val-Tyr) was the short-
est peptide that was able to act as a substrate for
renin and also could be shown to be a competitive
inhibitor of the renin-tetradecapeptide substrate re-
action [55, 56].
Poulsen, Burton and Haber [54] synthesized a
number of analogs that exhibited stronger inhibitory
effects than the parent octapeptide. The most suc-
cessful of the first group was characterized by sub-
stitution of the D-stereoisomer of leucine at position
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6 (His-Pro-Phe-His-Leu-D-Leu-Val-Tyr), immedi-
ately carboxyterminal to renin' s cleavage site. At
pH 5.5, its inhibitory constant with respect to the
tetradecapeptide substrate was 3 mo1es and with
respect to the protein substrate in plasma, 32 smoles.
The D-Leu substitution prevented cleavage of the
Leu-D-Leu bond by renin. Unfortunately, this inhib-
itor was inactive at pH 7.4 and could not be used in
physiologic studies. Other analogs that were soluble
and active at physiologic pH were then synthesized
[53]. The most potent of these (Pro-His-Pro-Phe-
His-Phe-Phe-Val-Tyr) is characterized by phenyl-
alanine substitutions for the leucine residues at ei-
ther side of the cleavage site and a proline residue at
the amino terminus of the peptide. This compound
was capable of inhibiting the action of renin on both
the tetradecapeptide and on its natural protein sub-
strate in plasma at pH 7.4 with nearly equal ef-
fectiveness.
Converting enzyme inhibitors. A series of pep-
tides originally isolated from snake venom are ef-
fective inhibitors of angiotensin-converting enzyme
[57]. They act to block the cleavage of angiotensin I
and thereby prevent the formation of angiotensin II
[58]. The synthetic nonapeptide Pyr-Trp-Pro-Arg-
Phe-Gln-Ile-Pro-Pro (Teprotide), based on the
structure of one of the natural snake venom pep-
tides [59], has now been used in both animal and
human studies, which will be described in detail
subsequently.
More recently, a new inhibitor of converting en-
zyme has become available. Ondetti et al [59] re-
ported the synthesis of D-3-mercapto-2-methyl-
propanoyl-L-proline (captopril), a relatively low
molecular weight compound which inhibits angio-
tensin-converting enzyme after oral administration
[60]. The application of this material in a clinical
study will be detailed later.
Competitive inhibitors of angiotensin II. Sarco-
sine 1alanine8-angiotensin II (Saralasin) [61], (Fig. 2)
is an example of a series of effective and specific
inhibitors [62] that compete with angiotensin II at
its receptor sites. These peptides are based on vari-
ants of the structure of angiotensin II. The critical
site of amino acid substitution, which determines
the efficacy of an inhibitor, is the carboxyterminal
position; substitutions at the amino terminal posi-
tion serve to enhance activity. These compounds
have now found both experimental and clinical ap-
plications [63-70].
Renin and sodium balance
The i.v. infusion of converting enzyme inhibitor
(CE!) has no discernible effect either on blood pres-
sure or PRA in a normal experimental animal main-
tained on adequate sodium intake [71-73]. The an-
giotensin II competitive inhibitor Saralasin results
in a brief pressor response in the normal animal, fol-
lowed by prompt return of blood pressure to normal
levels even though infusion of the drug may contin-
ue [63, 64].
Sodium deprivation, however, uncovers a very
different response [64]. We studied trained con-
scious animals that had undergone prior adrenal-
ectomy and were subsequently maintained on 25 mg
of cortisone and 1 mg of desoxycorticosterone ace-
tate [74]. On a normal intake of sodium (50 to 60
mEq/day), CE! did not lower blood pressure. On an
intake of 10 mEq of sodium per day, however, very
different results were obtained. Baseline blood
pressure levels were within the normal range. The
animal was alert and manifested normal activity and
behavior. Plasma renin activity was moderately ele-
vated. Upon administration of Saralasin, blood
pressure levels first increased 25 mm Hg and then
decreased 27 mm Hg below control levels. These
hemodynamic changes were associated with a strik-
ing rise in PRA. Blood pressure soon returned to
control levels coincident with a fall th renin activity.
The subsequent administration of CE! resulted in a
prompt decrease in blood pressure to the same de-
gree without the initial increase noted when Sarala-
sin was used. Renin activity also increased coinci-
dentally with the hemodynamic change in response
to both inhibitors. The results of these experiments
are consistent with earlier and subsequent reports
[61, 63, 64, 66, 67, 71, 72, 73, 75].
A decrease in blood pressure in a sodium-deplet-
ed animal consequent to blockade of the action by
renin by two very different methods suggests that,
in the presence of a limited extracellular fluid vol-
ume, the hormone plays a major role in blood pres-
sure maintenance. Is the immediate rise in renin ac-
tivity simply the result of baroreceptor stimulation
or reflex increase in sympathetic activity secondary
to a lowered blood pressure? Or are other mecha-
nisms involved? An answer is suggested by the fol-
lowing experiment [74]. A prolonged infusion of
CE! in a sodium-depleted adrenalectomized dog re-
sulted in hypotension throughout the duration of the
infusion. Renin activity increased until it reached
levels 12 times greater than that found in the control
period. When angiotensin II was infused at a suf-
ficient rate to maintain normal blood pressure dur-
ing the CEI infusion, renin activity did not increase.
These results indicate that if both blood pressure
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and angiotensin II concentration are maintained,
CEI alone does not alter PRA. If the aipha-adrener-
gic agonist phenylephrine, which itself has no effect
on renin activity, is used to maintain blood pressure
instead of angiotensin II during CEI blockade, an
increase in renin activity still occurs, though to a
somewhat lesser degree. To exclude reflex beta-ad-
renergic stimulation as a cause of renin release, a
blocking dose of propanolol was given prior to the
injection of the inhibitor. Even though heart rate did
not change as blood pressure decreased, PRA in-
creased significantly. These experiments indicate
that the rate of renin secretion is controlled by both
blood pressure and angiotensin II concentration.
These observations confirmed earlier experiments
that demonstrated negative feedback of angiotensin
II concentrations onto renin secretion rates both in
humans [76] and in other species [77-801. Blair-
West et al [811 showed that this inhibition could be
demonstrated at physiologic concentrations of the
hormone and that it was independent of changes in
renal arterial pressure and sodium concentration.
More recently Freedman, Davis, and Lohmeier [821
demonstrated that PRA decreases during infusion
of either angiotensin II or the heptapeptide des-i-
Asp-angiotensin II at rates that do not significantly
affect renal blood flow, arterial blood pressure, or
sodium excretion.
Studies in normal human subjects
Does the renin-angiotensin system come into play
only at the extremes of extracellular fluid volume
depletion, or does it also have a role in blood pres-
sure regulation at lesser degrees of physiologic
stress? Studies in human subjects have addressed
this question [83]. Four normal young subjects in
sodium balance with a 110 mEq/day intake were
first studied in the supine position, then tilted up-
right to 70° before and after administration of CEI.
The nature and duration of the tilting stress was ju-
diciously chosen so that none of the subjects would
become either hypotensive or faint. During the
study, heart rate and blood pressure were mon-
itored and frequent blood samples were obtained
for PRA and aldosterone concentration.
As can be seen from Figure 3, prior to the admin-
istration of CEI, upright tilting resulted in little he-
rnodynamic change, a minimal narrowing of pulse
pressure, and a slight tachycardia; however, a rise
in both PRA and plasma aldosterone concentration
occurred. The administration of CEI did not result
in significant hemodynamic changes either in the su-
Fig. 3. Representative example of a subject examined in the supine posture and during tilting while sodiu,n -replete and sodium-depleted
prior to and subsequent to the administration of converting enzyme inhibitor (CE!). BP = blood pressure; HR = heart rate, PRA
plasma renin activity, PA = plasma aldosterone. (Data taken from Ref. 83. Reprinted by permission from Circulation.)
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pine position or on tilting. Renin activity increased
both in the supine position and on tilting, but no
corresponding rise in aldosterone concentration
was apparent. After sodium depletion either by diet
or after the administration of a diuretic, an average
weight loss of 2.6 kg was observed. Supine renin
and aldosterone plasma values were higher during
the control period; the hemodynamic response to
tilting was somewhat more marked under these cir-
cumstances than with the higher sodium intake. Af-
ter administration of CE!, tilting was associated
with a striking decrease in blood pressure to hypo-
tensive levels accompanied by an even greater ele-
vation in renin activity; there was, remarkably, no
change in plasma aldosterone concentration.
To determine the effects of prolonged infusion of
CEI in the supine posture, another group of five
normal subjects was given 80 mg of furosemide;
they sustained a weight loss of 1.54 kg. The sub-
sequent administration of CEI was followed by a
transient drop in diastolic blood pressure associated
with a brief tachycardia. Blood pressure and heart
rate returned to control values and remained there
during a constant infusion of CEI for the next 145
minutes. Renin activity increased rapidly to very
high levels immediately after the initiation of CEI
infusion. At the same time, plasma aldosterone val-
ues decreased.
These observations in normal man given CEI ex-
tend and reinforce the conclusions of earlier experi-
ments in sodium-depleted animals. A marked de-
crease in blood pressure and an increase in heart
rate on tilting in sodium-depleted but not in sodium-
replete subjects, indicates that angiotensin II is an
essential element of blood pressure control, even in
states of only modest extracellular fluid volume de-
pletion. The increase of PRA in the supine position
subsequent to CEI infusion, in the absence of a de-
crease in blood pressure, suggests that angiotensin
II exerts direct feedback control on renin secretion.
The absence of the expected increase in plasma a!-
dosterone concentration after CEI infusion, both on
tilting or sodium depletion in the presence of an ex-
aggerated renin activity, suggests that angiotensin
II is the primary stimulus to aldosterone secretion
in response to sodium depletion or postural change.
Experimental renovascular hypertension
The role of renin in the genesis and maintenance
of renovascular hypertension has been subject to
conflicting interpretations and, at times, apparently
irreconcilable experimental data. An elevation in
renal vein renin activity has proved to be a most
useful diagnostic test for curable unilateral renal ar-
tery stenosis. Yet in chronic experimental or clini-
cal renovascular hypertension, PRA is often nor-
mal.
Acute experimental studies are difficult to inter-
pret because anesthesia, surgical trauma, and blood
loss all modify the response of the renin-angiotensin
system. Renal function has been shown to be al-
tered as long as I to 2 weeks after surgery [84]. To
circumvent some of these problems studies were
performed on trained, conscious animals appropri-
ately prepared and examined at least 2 weeks sub-
sequent to surgery [84]. The animals had undergone
unilateral nephrectomy. An external catheter a!-
lowed inflation of a cuff around the renal artery
while catheters proximal and distal to the cuff per-
mitted precise adjustment of the gradient created by
this stenosis. Blood samples could be obtained ei-
ther in the renal vein or in the vena cava.
A substantial gradient was established between
the aorta and the renal artery and was maintained at
a constant level by adjustment of the cuff [71]. A
rapid increase in mean aortic pressure to hyperten-
sive levels occured and was associated with an
early elevation of PRA. The administration of CE!
resulted in a prompt decrease in blood pressure to
near normotensive levels associated with a striking
increase in PRA. These observations indicated that
the renin-angiotensin system was responsible for
the initial increase in systemic blood pressure that
results from renal artery constriction. Blockade of
the conversion of angiotensin I to II promptly re-
duced blood pressure to normal.
When renal artery constriction was maintained
over a longer period persistent hypertension result-
ed, but PRA remained elevated for only a few days,
returning to control levels as sodium and water re-
tention occurred [84]. If angiotensin II levels are
prevented from increasing by continuous adminis-
tration of CEI after renal artery constriction, blood
pressure does not increase over a 4-day period in a
conscious one-kidney dog with renal artery con-
striction [72]. Once hypertension is established
however, inhibitors have little effect, indicating that
angiotensin II may not play a significant role in the
maintenance of chronic hypertension in the one-
kidney experimental preparation [61, 85, 86, 87].
Typical of these experiments is the study of Bump-
us et al [75] who reported that blockade with Sarala-
sin was effective in reducing blood pressure in the
conscious dog within 3 to 6 days after renal artery
constriction, but not later. Similarly, Johnson et al
[66] reported that Saralasin did not lower blood
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pressure in one-kidney Goldblatt dogs 2 to 7 weeks
after constriction of the renal artery. Thus, the de-
creasing effectiveness of CEI and angiotensin II an-
tagonists in lowering blood pressure in chronic one-
kidney renovascular hypertension suggests that
over time other factors begin to play an increasingly
important role in the maintenance of elevated blood
pressure.
What are these contributing factors? Tobian, Cof-
fee, and McCrea [88] and Guyton, Coleman, and
Granger [89] have stressed the importance of so-
dium and water retention in the maintenance of the
elevated blood pressure of chronic renovascular
hypertension. Tagawa et al [84] directly demon-
strated sodium retention and increased water intake
following the chronic constriction of the renal ar-
tery in a unilaterally nephrectomized dog with a
normal sodium intake. Gavras et al [64] showed that
in the sodium depleted one-kidney Goldblatt rat, Sa-
ralasin resulted in a large decrease in blood pres-
sure, whereas after sodium repletion no decrease in
blood pressure could be demonstrated with this
agent. More recently, Rocchini and Barger pro-
duced reversible renal artery stenosis in seven
trained, unanesthetized dogs maintained on a diet
containing less than 10 mEq of sodium a day [90].
Renal artery perfusion pressure was reduced to 60
to 70 mm Hg, and blood pressure increased 37 4
mm Hg within 1 hour of constriction, remaining at
this level throughout the experiment. Presumably
because of the low sodium intake, fluid and sodium
retention did not occur, as confirmed by balance
studies. There was no change in hematocrit, weight,
or plasma volume. Plasma renin activity as well as
plasma aldosterone concentration increased and re-
mained elevated through 14 days of study. At the
end of 14 days, the animals were exquisitely sensi-
tive to CEI. In contrast to animals on an ad lib so-
dium intake, which are unresponsive to CEI, blood
pressure returned to normal within 5 minutes of an
i.v. bolus injection of the drug. Thus, unlike the
findings in experimental models in which a normal
sodium intake is permitted, when sodium and fluid
accumulation is prevented by dietary sodium re-
striction one-kidney renovascular hypertension is
characterized by a persistently elevated renin activ-
ity. The evidence, therefore, seems to point to so-
dium and water retention as the principal factors in
the maintenance of persistent hypertension in the
one-kidney animal with renal artery constriction.
There seem to be two phases of renovascular hy-
pertension: (1) an initial phase in which elevated
blood pressure is maintained by the direct pressor
actions of angiotension II; and (2) a later chronic
phase in which blood pressure is maintained largely
as a result of hypervolemia, mediated by sodium
and water retention. Whether sodium retention is
simply the direct effect of diminished renal arterial
pressure on kidney function or whether it is mediat-
ed indirectly via angiotensin II through its action on
mineralocorticoid secretion remains to be deter-
mined.
The long-term role of renin in mediating sodium
retention and hypertension in one-kidney reno-
vascular hypertension has recently been tested by
Watkins et al [91]. The administration of Saralasin
or CEI to one-kidney renovascular hypertensive
dogs did not block the development of blood pres-
sure elevation suggesting a lack of participation of
the renin-angiotensin system under these circum-
stances although some of their experimental inter-
pretations can be challenged, Skeggs et al [85, 92,
93] came to similar conclusions. They showed that
hypertension in a one-kidney rabbit model could
not be ameliorated by renin-specific antibody nor
by the angiotensin II inhibitor Saralasin. They did,
however, demonstrate that blood pressure could be
lowered to normal by immunization with a hog kid-
ney cortex preparation that did not contain renin.
The passive transfer of antibody preparations spe-
cific for this material had the same effect. When ren-
al cortex preparations were injected directly, a de-
layed slow increase in blood pressure occurred that
persisted indefinitely, even after the injections were
stopped. Skeggs Ct al postulate the participation of
a new hypertensive substance they named reno-
pressin.
Boucher et al have isolated an enzyme, tonin,
from the rat's submaxillary gland that acts directly
on renin substrate to release angiotensin II without
the intermediate prohormone angiotensin I [94]. It
has been fully purified recently and shown to be dif-
ferent from renin. Administration of rabbit tonin
antiserum resulted in a decrease in blood pressure
to normal in 7 of 10 one-kidney hypertensive ani-
mals, whereas very little change in blood pressure
was observed in two-kidney, one-clip hypertensive
animals or in a control group [95]. These workers
postulate that in rabbits with chronic one-kidney
hypertension tonin might be the responsible media-
tor. It is difficult to be sure whether or not tonin is
the same substance as the renopressin of the Skeggs
investigations. In any event, further detailed char-
acterization of these factors is needed before they
can be implicated with certainty in the etiology of
experimental renovascular hypertension.
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Renin-dependent hypertension in human subjects
Although the etiologic role of the renin-angioten-
sin system in chronic renovascular hypertension re-
mains to be established, it is generally agreed that
the determination of renin activity in renal venous
blood is a most useful diagnostic aid. When renal
vein renin activity from the affected kidney is great-
er than that of the uninvolved side, the probability
of improvement in blood pressure after surgery is
considerable [96-100].
To increase the sensitivity and reliability of renal
vein sampling, a variety of stimulatory maneuvers
including diuretic administration, vasodilator ad-
ministration, and upright posture have been used
[96, 101—105]. Most recently, Re et al [106] used
CE! in the study of a series of unselected hyperten-
sive patients undergoing bilateral renal vein cathe-
terization. In the group of patients (group I) who
were later shown to have predominately unilateral
renal artery stenosis demonstrated by contrast stud-
ies, the ratio of involved to uninvolved renal PRA
increased from 2.94 0.91 before to 8.36 2.94
after CEI administration (Fig. 4). In the group
(group II) that did not have a renal artery abnormal-
ity, the ratio of the initially higher to lower side was
1.99 0.49 before and 1.17 0.07 after the admin-
istration of CEI, a nonsignificant difference. Plasma
renin activity after the administration of CE! was
predictable by the measurement of pretreatment
PRA. Mean blood pressure decreased in both
groups, but the decrement was predicted by PRA
prior to CEI administration. Thus, CE!, probably
because of its interference in the angiotensin II neg-
ative feedback 1oop, increases renin secretion in the
affected kidney in unilateral renal artery stenosis far
more than in the unaffected kidney. This results in
increased diagnostic accuracy by magnifying the
PRA difference between the two sides.
Several investigators have suggested that a de-
crease in blood pressure in response either to CEI
or to angiotensin II analogs may be of value in iden-
tifying patients with renin-dependent hypertension
[68—70, 107]. Gavras et al [107] stress that sensitivi-
ty of detection may increase if subjects have been
previously sodium depleted. A decrease in blood
pressure under these circumstances must be inter-
preted with the greatest caution. It may indicate on-
ly that blood pressure maintenance is in part depen-
dent on angiotensin II, a normal physiologic state in
volume- or sodium-depleted individuals. Utilization
of inhibitors in the identification of renin-dependent
hypertension may require that testing be carried out
while subjects are in a state of normal sodium bal-
0 ___ ____
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Fig. 4. Mean (± SE renal vein plasma renin activity (PRA) ratio
before (dots) and after (diagonal bars) converting enzyme inhib-
itor (CE!) in Group I and Group II patients. Dashed line in-
dicates a ratio of 1.5. (Data taken from Ref. 106. Reprinted by
permission from the New England Journal of Medicine.)
ance. For example, a 28-year-old woman with
chronic bilateral pyelonephritis and persistent hy-
pertension was studied while in sodium balance
through a daily sodium intake of 110 mEq. Plasma
renin activity was abnormally elevated at 8.0 ng!mlJ
hr (normal values using this diet are 1.02 0.21 ng/
mllhr). The administration of CE! resulted in a
prompt decrease in blood pressure to the normoten-
sive range. There was a further increase in PRA ac-
companied by a decrease in plasma aldosterone,
which confirmed blockade of angiotensin produc-
tion.
It is of interest that clinical studies with the oral
angiotensin CE! discussed above (captopril) appear
to give somewhat different results from those with
the nonapeptide inhibitor. Gavras et al [108] report
no significant correlation between pretreatment
PRA and the degree of blood pressure decrease
with this agent, in contrast to the findings of Re et al
[106] discussed previously. Another interesting ob-
servation is that the oral CE! is equally effective in
lowering blood pressure in renovascular hyper-
tension and essential hypertension suggesting that,
although useful in renin-dependent hypertension, it
may well have other hypotensive actions independ-
ent of converting enzyme blockade. Oral CEI may
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not prove to be as valuable as a diagnostic agent in
the identification of renovascular hypertensives as
other nonspecific converting enzyme inhibitors.
Turning again to consideration of the patient pre-
sented today, it would be desirable to determine
whether or not renin is really contributing to the
maintenance of his blood pressure prior to pro-
ceeding with any serious consideration of operative
intervention. In the absence of antihypertensive
medications and with a normal sodium intake of 100
mEqiday, CEI should be given intravenously as a
test. If blood pressure decreases in the supine posi-
tion, it is likely that renin is responsible for the pa-
tient's blood pressure elevation. If, on the other
hand, the agent has no effect on blood pressure, it
would be injudicious to pursue further diagnostic
measures with respect to potential renin-secreting
lesions in the lower pole of the left kidney. If the
oral CEI became available to this patient, he cer-
tainly could be given a therapeutic trial; if success-
ful, neither further invasive diagnostic measures
nor operative intervention may prove necessary.
But if medical management continues to be difficult
or impossible, it would be highly desirable to try to
incriminate the lower pole of the kidney as a source
of excess renin secretion. Renal vein catheteriza-
tion could be repeated after the administration of
nonapetide GET to determine whether the ratio of
renin secretion among the several branches of the
left renal vein was altered dramatically; if it were,
an operative attack on the lower pole might be in-
dicated. The risk to this patient's life from contin-
ued uncontrolled hypertension is likely to be greater
than the risk of ablating the lower pole of a sole kid-
ney.
Questions and Answers
DR J. J. COHEN: You raised the very interesting
possibility that the increased renin secretion in this
patient might be due to accelerated hypertension; in
other words, that it is simply a fixed consequence of
his long-standing extreme hypertension. The curi-
ous thing about this man's accelerated hyper-
tension, as you pointed out, is the absence of evi-
dent renal disease; he has no proteinuria and no re-
nal functional impairment. Do patients whose
kidneys are spared, for whatever reason, during the
course of accelerated hypertension also develop hy-
perreninemia. If so, how do you account for that?
DR. E. HABER: I think you have hit the nail right
on the head. Patients who are hyperreninemic with
accelerated hypertension almost invariably have
renal damage. In my view, the cause of the hyper-
reninemia is diffuse renal arteriolar narrowing either
on a functional or structural basis, which has the
same net effect as a major stenosis in the main renal
artery. The result is diminished renal blood flow and
eventually renal parenchymal damage.
DR. N. E. MADIAS (NEMCH): It has been sug-
gested that 40% of patients with renovascular hy-
pertension have normal peripheral PRA. Do you
know of any particular characteristics that dif-
ferentiate such individuals from those with reno-
vascular hypertension and elevated peripheral
PRA?
DR. E. HABER: I agree that peripheral PRA is
probably an unreliable test for renovascular hyper-
tension exactly for the reason you state; almost half
of the patients have normal values. The probable
explanation is that these patients have reached the
stage of their disease at which sufficient sodium and
volume are retained to normalize renin activity. The
hypertension has become volume dependent.
DR. J. T. HARRINGTON: Have you had the oppor-
tunity to study the effects of blocking or inhibiting
agents in transplant recipients with renal artery ste-
nosis? That would seem to be an ideal group to look
at.
DR. E. HABER: We have not as yet studied renal
transplant patients but would like to.
DR. J. J. COHEN: Apparently, there is some circu-
lating activity of converting enzymes. Is there any
diagnostic value in measuring the level of circulat-
ing converting enzymes?
DR. E. HABER: No, I don't think so. Measuring
circulating enzymes might be of value, however, in
determining the dose of an inhibitor. I know of no
pathologic state in which the converting enzyme it-
self is limiting; that is, there are no causes of hypo-
tension attributable to an insufficiency of the en-
zyme nor causes of hypertension attributable to an
excess. The capacity of the system is in excess of
what is needed.
DR. J. T. HARRINGTON: Has CEI been used in
experimental models of acute renal failure?
DR. E. HABER: Yes, it has and there have been
contradictory results. Initially, there was interest in
the demonstration of a greater survival rate in ani-
mals with experimental acute renal failure treated
with CEI, but the subsequent experiments have not
reproduced this observation.
DR. J. J. COHEN: To return to our patient, we
were intrigued with the possibility that he might
have a small renin-secreting tumor in the lower pole
of his solitary kidney. Surgery was discussed with
him, but he has been understandably resistent to the
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idea. In addition to the obvious risks, another as-
pect of the surgical alternative has bothered me.
Knowing that the patient has had hypertension for
at least 10 years, I wonder if there is precedent for a
renin-secreting tumor being present over such a
long period and still not being detectable by a good
angiographic study.
DR. E. HABER: One of the patients reported by
Conn et al [9] had 6 years of hypertension clearly
due to a tumor; when it was removed, blood pres-
sure normalized. The tumor was very small and dif-
ficult to see even during surgery. Renin-secreting
tumors are generally benign and slow growing; they
seldom metastasize, and they secrete a great deal of
renin for their size. It is conceivable that a tumor
could be present for 10 years in this patient and yet
not be obvious.
DR. J. J. COHEN: Surgical intervention in a pa-
tient with a solitary kidney obviously carries con-
siderably more risk than in a patient blessed with
two kidneys. If we were able to exclude renal artery
stenosis and confirm a diagnosis of renin-dependent
hypertension, what would be your specific recom-
mendations for management of the patient?
DR. E. HABER: I think the patient's prognosis is
poor in view of complications already manifest. He
has damage both to his central nervous and his car-
diovascular systems; fortunately, he does not have
renal damage yet. I would take the risk of examin-
ing the lower pole of his kidney by direct visual-
ization if needed. Of course, a second angiographic
study should be done first.
DR. J. J. COHEN: Yes, I think it should. In addi-
tion, would you consider a trial of oral CEI worth-
while in this patient?
DR. E. HABER: Yes, he may respond favorably.
As I indicated, if he has a tumor it is likely to be
benign and grow slowly. In a case reported by Rob-
ertson et al [8], the tumor was missed on repeated
review of one angiographic study, but 2 years later
it was seen on a subsequent angiogram, which
means that they do grow albeit slowly. Surgery
could be considered with a great deal more con-
fidence if the diagnosis of tumor could be made by
angiography.
DR. J. 3. COHEN: Even if we had definite evi-
dence that a tumor was present, the patient still has
a single kidney and the operative risk is consid-
erable. Under those circumstances, would you still
attack it surgically or would you elect a medical al-
ternative and use an oral CEI?
DR. E. HABER: There is no followup study on re-
nm-producing tumors treated with CEI. I would,
however, feel uncomfortable about leaving a diag-
nosed tumor in place. I would take the risk of sur-
gery, particularly if the tumor were located at the
lower pole of the kidney facilitating its removal
without endangering the rest of the organ.
Reprint requests to Dr. Edgar Haber, Cardiac Unit, Massa-
chusetts General Hospital, Boston, Massachusetts 02114
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The editors should like to expand the scope of these exercises by encouraging active partici-
pation of the journal's readership in Nephrology Forum. Questions or comments pertaining to
this month's discussion may be submitted to Nephrology Forum, Box 212, New England Medi-
cal Center Hospital, 171 Harrison Avenue, Boston, Massachusetts 02111. Correspondence
received by May 30, 1979 will be eligible for inclusion in a forthcoming installment.
